ADMA Biologics Inc撤回长期业绩指引主因血浆制品与免疫球蛋白市场竞争加剧

美股速递05-07 04:24

鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1122459342?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-07 04:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1122459342","market":"us","top_or_hot":-1,"title":"ADMA Biologics Inc撤回长期业绩指引 主因血浆制品与免疫球蛋白市场竞争加剧","media":"美股速递","content":"<p>鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ADMA Biologics Inc撤回长期业绩指引 主因血浆制品与免疫球蛋白市场竞争加剧</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nADMA Biologics Inc撤回长期业绩指引 主因血浆制品与免疫球蛋白市场竞争加剧\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-07 04:24 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1122459342","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1122459342","pubTimestamp":1778099068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","ADMA":"ADMA Biologics Inc"},"translate_title":"ADMA Biologics Inc withdraws long-term performance guidance mainly due to increased competition in the plasma products and immunoglobulin markets","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADMA":1},"content_text":"鉴于血浆制品(PDT)与免疫球蛋白(Ig)市场日益激烈的竞争态势，ADMA Biologics Inc决定撤回其长期业绩指引。这一调整反映出当前行业竞争格局对该公司未来增长预期产生的实质性影响。市场动态的快速演变迫使企业重新评估原有战略规划，以更灵活的姿态应对不确定性。此次指引撤回也向投资者传递出管理层对市场环境变化的审慎态度，预示着行业可能进入新一轮调整周期。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1122459342","isCrawlerRequest":true}

ADMA Biologics Inc撤回长期业绩指引 主因血浆制品与免疫球蛋白市场竞争加剧

精彩评论

ADMA Biologics Inc撤回长期业绩指引主因血浆制品与免疫球蛋白市场竞争加剧